PHILADELPHIA, May 9 /PRNewswire-FirstCall/ -- Biofield Corporation announced today that it has launched a new website to showcase its new leadership and an expanded vision for rapid growth and global recognition. Key elements of this expansion include a ramped-up marketing initiative to build distribution networks in the European Union, Hong Kong, Philippines and Korea, along with aggressive exploration of manufacturing partnerships in China.
In addition, Mr. Michael Yom, Biofield's president, recently welcomed respected biochemist Dr. Ram Roy to Biofield's Board of Advisors. Dr. Roy has led a distinguished 30-year career in both academia as a professor at Princeton University, MIT and other prestigious institutions, and in the private sector as a biochemist and clinical researcher in the pharmaceutical, food science and medical devices industries. He has published over 100 professional papers and is recognized for his expertise in new product and process development.
Mr. Yom states, "Given the rapid increase in worldwide cancer rates and the need for early detection, Biofield's technology has never been more critical. We are honored that Dr. Roy has agreed to share his vast experience to help build upon our technological achievements while we look to sales and manufacturing overseas."
Certain statements made in this press release should be considered forward-looking and subject to various risks and uncertainties. Such forward-looking statements are based on management's belief, as well as assumptions made by, and information currently available to, management pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements can generally be identified as such because the context of the statement will include words such as "believes," "anticipates," "appears," "expects," "should," "may," or words of similar import. Similarly, statements that describe the company's future plans, objectives, estimates or goals are also forward-looking statements. Such statements may address future events and conditions concerning, among other matters, (i) the ability of the company to obtain sufficient funding in order to maintain operations, complete its FDA application and have its equipment manufactured and (ii) the granting of approval by the FDA of the company's Breast Proliferation Detection System, which may not occur or, if it does, may not be timely. Additional factors which should be considered are set forth in the company's Annual Report on Form 10-KSB for its fiscal year ended December 31, 2004 and Quarterly Report on Form 10-QSB for its fiscal quarter ended Sept. 30, 2005. Copies of such documents can be obtained from the EDGAR database Internet web site maintained by the Securities and Exchange Commission at http://www.sec.gov/edgarhp.htm. The company undertakes no obligation to release publicly the results of any revisions to its forward-looking statements that may be made in this press release to reflect events or circumstances occurring after the date of this press release.
Biofield Corp.CONTACT: Michael Yom of Biofield Corp., +1-215-972-1717, or fax,+1-215-972-6988, or mobile, +1-215-520-2525, or myom@biofield.com
Web site: http://www.biofield.com/
